| pubmed-article:8120551 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8120551 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8120551 | lifeskim:mentions | umls-concept:C0205282 | lld:lifeskim |
| pubmed-article:8120551 | lifeskim:mentions | umls-concept:C0280100 | lld:lifeskim |
| pubmed-article:8120551 | lifeskim:mentions | umls-concept:C0146224 | lld:lifeskim |
| pubmed-article:8120551 | lifeskim:mentions | umls-concept:C1521725 | lld:lifeskim |
| pubmed-article:8120551 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:8120551 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8120551 | pubmed:dateCreated | 1994-4-4 | lld:pubmed |
| pubmed-article:8120551 | pubmed:abstractText | To determine the dose-limiting toxicity and potential efficacy of topotecan in pediatric patients with refractory malignant solid tumors. | lld:pubmed |
| pubmed-article:8120551 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8120551 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8120551 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8120551 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8120551 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8120551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8120551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8120551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8120551 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8120551 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8120551 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:PrattC BCB | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:StewartCC | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:FurmanWW | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:HeidemanRR | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:BowmanLL | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:OchsJJ | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:SantanaV MVM | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:KutteschJ FJF | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:MarinaNN | lld:pubmed |
| pubmed-article:8120551 | pubmed:author | pubmed-author:SandlundJ TJT | lld:pubmed |
| pubmed-article:8120551 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8120551 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:8120551 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8120551 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8120551 | pubmed:pagination | 539-43 | lld:pubmed |
| pubmed-article:8120551 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:meshHeading | pubmed-meshheading:8120551-... | lld:pubmed |
| pubmed-article:8120551 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8120551 | pubmed:articleTitle | Phase I study of topotecan for pediatric patients with malignant solid tumors. | lld:pubmed |
| pubmed-article:8120551 | pubmed:affiliation | Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, TN 38101-0318. | lld:pubmed |
| pubmed-article:8120551 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8120551 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8120551 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8120551 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8120551 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8120551 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8120551 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8120551 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8120551 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8120551 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8120551 | lld:pubmed |
